<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23569" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Insulinoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zhuo</surname>
            <given-names>Fenghao</given-names>
          </name>
          <aff>Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anastasopoulou</surname>
            <given-names>Catherine</given-names>
          </name>
          <aff>Jefferson Einstein Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Fenghao Zhuo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Catherine Anastasopoulou declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23569.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Insulinoma is a type of functional neuroendocrine tumor characterized by hypersecretion of insulin, causing hypoglycemia. It typically presents as a solitary benign tumor but can be associated with multiple endocrine neoplasia type 1 (MEN1). Patients with insulinoma have hypoglycemic episodes, more characteristically as fasting hypoglycemia. Insulinoma is usually diagnosed by biochemical testing. Surgical resection is the preferred treatment choice. This activity reviews the manifestations, evaluation, and treatment of insulinoma and highlights the importance of an interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the typical presenting symptoms of insulinoma.</p></list-item><list-item><p>Review the evaluation of insulinoma, including appropriate biochemical tests and localization modalities.</p></list-item><list-item><p>Summarize the management of insulinoma.</p></list-item><list-item><p>Outline the importance of collaboration of an interprofessional team in managing insulinoma to improve the patient quality of care.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23569&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23569">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23569.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Insulinoma is a type of functional neuroendocrine tumor (NET) that manifests with hypoglycemia caused by inappropriately high insulin secretion. It more commonly presents as a solitary benign tumor, but it&#x000a0;can sometimes be associated with multiple endocrine neoplasia type 1 (MEN1). Patients with insulinoma have hypoglycemic episodes, more characteristically as fasting hypoglycemia. Insulinoma&#x000a0;is usually diagnosed by biochemical testing when there is high clinical suspicion. Surgical resection is the preferred treatment choice. Localization with imaging studies is fundamental to characterize the tumor better before surgical resection. Other treatment options are also available depending on the stage and grade of the tumor.</p>
      </sec>
      <sec id="article-23569.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of solitary insulinoma is not clearly understood. Normally high plasma glucose concentration would trigger the secretion of insulin from the pancreatic beta cells and vice versa. In patients with insulinoma, insulin still gets secreted, even when plasma glucose concentration is low. Hyperinsulinemia could result from an upregulated translation process due to a variant of insulin splice.<xref ref-type="bibr" rid="article-23569.r1">[1]</xref>&#x000a0;When the intracellular insulin store has been filled up, insulin gets secreted into the blood. Hyperinsulinemia causes increased glycogen synthesis, decreased gluconeogenesis, and glycogenolysis, all of which attribute to hypoglycemia.</p>
        <p>MEN1 is a disorder characterized by a predisposition to the pituitary, parathyroid, and enteropancreatic tumors. When insulinomas are associated with MEN1, a mutation in the MEN1 gene at chromosome 11q13 is typically present in&#x000a0;most cases.<xref ref-type="bibr" rid="article-23569.r2">[2]</xref></p>
      </sec>
      <sec id="article-23569.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of insulinoma is around 1 to 4 per million per year.<xref ref-type="bibr" rid="article-23569.r3">[3]</xref><xref ref-type="bibr" rid="article-23569.r4">[4]</xref>&#x000a0;More commonly, insulinoma&#x000a0;is a&#x000a0;single benign tumor; in 5.8% of cases, it can be&#x000a0;malignant.<xref ref-type="bibr" rid="article-23569.r3">[3]</xref>&#x000a0;It can&#x000a0;coexist with other benign tumors in 7% of the cases, and in 6% to 7.6% of the cases,&#x000a0;it is&#x000a0;associated with MEN1 syndrome.<xref ref-type="bibr" rid="article-23569.r3">[3]</xref><xref ref-type="bibr" rid="article-23569.r5">[5]</xref>&#x000a0;Surgical diagnosis&#x000a0;happens at a median age of 47 to 50 years old.<xref ref-type="bibr" rid="article-23569.r3">[3]</xref><xref ref-type="bibr" rid="article-23569.r5">[5]</xref></p>
      </sec>
      <sec id="article-23569.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Fasting hypoglycemia is&#x000a0;the most&#x000a0;characteristic&#x000a0;finding of insulinoma, reported in 73% of the population.<xref ref-type="bibr" rid="article-23569.r5">[5]</xref>&#x000a0;Around 20% of patients have both fasting and postprandial hypoglycemic symptoms.<xref ref-type="bibr" rid="article-23569.r5">[5]</xref>&#x000a0;There have been increasing numbers of patients reporting only postprandial hypoglycemic symptoms, which is more prominent in men.<xref ref-type="bibr" rid="article-23569.r5">[5]</xref>&#x000a0;Weight gain occurs in most of these patients.</p>
        <p>Hypoglycemia&#x000a0;presents in&#x000a0;different ways. Sympathoadrenal activation symptoms can be seen, including palpitations, tremulousness, and diaphoresis. Severe hypoglycemia can cause neuroglycopenic symptoms, including blurry vision, confusion, seizures,&#x000a0;or a behavioral change. Amnesia of the hypoglycemic event is common.<xref ref-type="bibr" rid="article-23569.r6">[6]</xref></p>
        <p>Insulinoma should be suspected when a&#x000a0;patient presents with the Whipple&#x02019;s triad, which includes: symptoms of hypoglycemia, a documented&#x000a0;low plasma glucose concentration, and subsequent&#x000a0;improvement of the symptoms with the use of glucose treatment.&#x000a0;</p>
        <p>In rare cases reported in the literature, the insulinoma may present with psychiatric symptoms, especially panic attacks.<xref ref-type="bibr" rid="article-23569.r7">[7]</xref></p>
      </sec>
      <sec id="article-23569.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>There are two crucial steps in evaluating an insulinoma. The first is to establish the diagnosis with biochemical tests when there is high clinical suspicion, and the second is to&#x000a0;localize the tumor.</p>
        <p>A 72-hour fast is the gold-standard test for diagnosing insulinoma.<xref ref-type="bibr" rid="article-23569.r4">[4]</xref><xref ref-type="bibr" rid="article-23569.r8">[8]</xref>&#x000a0;It is useful when the Whipple triad is not observable and when there were no biochemical tests during spontaneous hypoglycemic episodes.&#x000a0;<xref ref-type="bibr" rid="article-23569.r9">[9]</xref>&#x000a0;The combination of plasma glucose concentration under 55 mg/dL, insulin level greater than or equal to 3 microUnits/mL, C peptide level greater than or equal to 0.6 ng/mL, proinsulin level greater than or equal to 5 pmol/L, beta-hydroxybutyrate level less than or equal to 2.7 mmol/L and a simultaneous&#x000a0;negative sulfonylurea level&#x000a0;indicates that the hypoglycemia induction is by hyperinsulinemia.</p>
        <p>A&#x000a0;successful preoperative localization&#x000a0;by non-invasive modalities remains around 75%.<xref ref-type="bibr" rid="article-23569.r5">[5]</xref>&#x000a0;Computed tomography (CT) with contrast is the most frequently used initial non-invasive testing.<xref ref-type="bibr" rid="article-23569.r8">[8]</xref>&#x000a0;CT detects 70 to 80% of the tumors&#x000a0;where the insulinoma&#x000a0;usually&#x000a0;presents as a small solid mass, enhancing after contrast.<xref ref-type="bibr" rid="article-23569.r10">[10]</xref><xref ref-type="bibr" rid="article-23569.r11">[11]</xref>&#x000a0;Abdominal ultrasound (US) focusing on the pancreas is sometimes preferred, given its convenience and low cost. Magnetic resonance image (MRI) detects about 85% of the insulinomas that seem to&#x000a0;enhance homogeneously after gadolinium administration.<xref ref-type="bibr" rid="article-23569.r10">[10]</xref><xref ref-type="bibr" rid="article-23569.r11">[11]</xref>&#x000a0;Glucagon-like peptide-1 receptor (GLP-1) imaging is a promising new modality test and has been studied to localize insulinoma with a successful detection rate of 66 to 97% in some&#x000a0;small studies.<xref ref-type="bibr" rid="article-23569.r12">[12]</xref><xref ref-type="bibr" rid="article-23569.r13">[13]</xref><xref ref-type="bibr" rid="article-23569.r14">[14]</xref><xref ref-type="bibr" rid="article-23569.r15">[15]</xref>&#x000a0;In animal models, PET and SPECT scans using radiolabeled excedin-4 helped localize the insulinoma in mice.<xref ref-type="bibr" rid="article-23569.r16">[16]</xref></p>
        <p>When there is a high suspicion of insulinoma with negative non-invasive studies, invasive tests such as endoscopic ultrasonography (EUS) or a selective arterial calcium stimulation test (SACST) with hepatic venous sampling could be considered. EUS has a sensitivity of 70 to 95% and is superior to CT for localization. <xref ref-type="bibr" rid="article-23569.r10">[10]</xref><xref ref-type="bibr" rid="article-23569.r17">[17]</xref><xref ref-type="bibr" rid="article-23569.r18">[18]</xref>&#x000a0;This is the preferred test of choice if non-invasive studies are negative. It also allows tissue acquisition which can be very helpful, especially&#x000a0;in small tumors.<xref ref-type="bibr" rid="article-23569.r17">[17]</xref>&#x000a0;SACST has a sensitivity of 93% for detecting insulinoma and could be&#x000a0;performed when other imaging studies are negative or in patients with MEN1 syndrome.<xref ref-type="bibr" rid="article-23569.r5">[5]</xref><xref ref-type="bibr" rid="article-23569.r19">[19]</xref></p>
        <p>Histology examination and immunostaining for chromogranin A, synaptophysin, and insulin should be done to support the diagnosis of insulinoma.<xref ref-type="bibr" rid="article-23569.r4">[4]</xref>&#x000a0;A Ki67 index should also be obtained for grading, especially when a patient demonstrates an aggressive clinical course.<xref ref-type="bibr" rid="article-23569.r4">[4]</xref></p>
        <p>Tumor size of greater than or equal to 2 cm, Ki67 more than 2%, and molecular features including chromosomal alteration such as 3p and 6q loss and 12 q gain&#x000a0;or chromosomal instability, are possible predictors for metastatic disease and poor progression-free survival (PFS).<xref ref-type="bibr" rid="article-23569.r20">[20]</xref></p>
        <p>Malignant insulinomas have evidence of extrapancreatic regional lymph nodes or even remote extension. Certain factors include fasting time for hypoglycemia being under 8 hours, higher blood insulin level (greater than or equal to 28 microUnits/mL), and higher C-peptide level (greater than or equal to 4.0 ng/mL) at the glycemic nadir. These factors, as well as larger tumor size (greater than or equal to 2.5 cm), all correlate with an increased risk of malignant disease.<xref ref-type="bibr" rid="article-23569.r21">[21]</xref>&#x000a0;The extent of liver metastases and the presence of lymph node metastases are important prognostic factors.<xref ref-type="bibr" rid="article-23569.r19">[19]</xref><xref ref-type="bibr" rid="article-23569.r22">[22]</xref><xref ref-type="bibr" rid="article-23569.r23">[23]</xref></p>
        <p>The recommendation is that all young patients with insulinoma undergo genetic testing. MEN1 syndrome should be considered in patients with family and/or personal histories of other endocrinopathies.<xref ref-type="bibr" rid="article-23569.r24">[24]</xref></p>
      </sec>
      <sec id="article-23569.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Surgical resection is recommended for local disease but should also be considered for advanced disease.<xref ref-type="bibr" rid="article-23569.r20">[20]</xref>&#x000a0;Single sporadic insulinoma is curable by surgical intervention.<xref ref-type="bibr" rid="article-23569.r4">[4]</xref>&#x000a0;Surgeons have described several different surgical approaches. The most common&#x000a0;of these is enucleation of the insulinoma and partial distal pancreatectomy.<xref ref-type="bibr" rid="article-23569.r3">[3]</xref>&#x000a0;Nowadays, laparoscopic resection of insulinoma is gaining in popularity with a shorter hospital stay and at least similar favorable&#x000a0;outcomes.<xref ref-type="bibr" rid="article-23569.r25">[25]</xref>&#x000a0;Preoperatively the patients can be treated with diazoxide or somatostatin analogs as tolerated.<xref ref-type="bibr" rid="article-23569.r26">[26]</xref><xref ref-type="bibr" rid="article-23569.r25">[25]</xref>&#x000a0;Robotic enucleation of insulinoma is being reported in some cases with good short and long-term outcomes compared to the laparoscopic approach.<xref ref-type="bibr" rid="article-23569.r27">[27]</xref><xref ref-type="bibr" rid="article-23569.r28">[28]</xref>&#x000a0;Patients with MEN1 might need a different surgical approach, including subtotal pancreatectomy in addition to enucleation of the&#x000a0;tumors. EUS-guided ethanol ablation has been attempted in poor surgical candidates and&#x000a0;has been&#x000a0;successful in some case series.<xref ref-type="bibr" rid="article-23569.r19">[19]</xref><xref ref-type="bibr" rid="article-23569.r29">[29]</xref><xref ref-type="bibr" rid="article-23569.r30">[30]</xref><xref ref-type="bibr" rid="article-23569.r31">[31]</xref></p>
        <p>Clinicians can attempt medical treatment before surgery in recurrent or malignant cases.<xref ref-type="bibr" rid="article-23569.r19">[19]</xref>&#x000a0;For initial insulinomas, dietary modification, diazoxide, everolimus, and MedicAlert bracelets are prudent steps.<xref ref-type="bibr" rid="article-23569.r24">[24]</xref>&#x000a0;Other strategies, including glucagon pen, somatostatin analogs, and steroids, are also considerations.<xref ref-type="bibr" rid="article-23569.r24">[24]</xref></p>
        <p>If the tumor is unresectable, if&#x000a0;the patient has metastatic disease, or if he&#x000a0;is a poor surgical candidate, diazoxide is an option.<xref ref-type="bibr" rid="article-23569.r9">[9]</xref>&#x000a0;Diazoxide can decrease insulin release and enhance glycogenolysis. Around 60% of the patients become symptom-free.<xref ref-type="bibr" rid="article-23569.r32">[32]</xref>&#x000a0;The efficacy of octreotide in patients with refractory hypoglycemia is less predictable but remains an option for patients who do not respond to diazoxide. For patients with refractory symptoms and stable tumor volume, adjusting the dose of octreotide or getting surgical resection could be considered.<xref ref-type="bibr" rid="article-23569.r24">[24]</xref></p>
        <p>For patients with refractory symptoms and increasing tumor volume, oncologic control&#x000a0;with referral to specialty centers&#x000a0;is recommended.<xref ref-type="bibr" rid="article-23569.r24">[24]</xref>&#x000a0;For patients with well-differentiated pancreatic neuroendocrine tumors (pNET), targeted therapy (everolimus or sunitinib) is a pharmaceutical option.<xref ref-type="bibr" rid="article-23569.r33">[33]</xref>&#x000a0;Everolimus inhibits the mammalian target of rapamycin.<xref ref-type="bibr" rid="article-23569.r34">[34]</xref>&#x000a0;Everolimus was found to improve median PFS in patients with low or intermediate-grade, advanced progressive pNET and a subgroup of functional pNET, including but not limited to insulinomas.<xref ref-type="bibr" rid="article-23569.r35">[35]</xref><xref ref-type="bibr" rid="article-23569.r36">[36]</xref>&#x000a0;It can also help to control hypoglycemia in patients with malignant insulinoma.<xref ref-type="bibr" rid="article-23569.r19">[19]</xref>&#x000a0;Last, sunitinib is also recommended for progressive metastatic pNET, although only a small number of patients with insulinoma participated in these studies.<xref ref-type="bibr" rid="article-23569.r24">[24]</xref><xref ref-type="bibr" rid="article-23569.r37">[37]</xref></p>
        <p>For advanced disease, surgical resection could still be an option if most (90% or more) of the tumor is safely resectable or if the liver metastases seem to be resectable.<xref ref-type="bibr" rid="article-23569.r24">[24]</xref>&#x000a0;There has not been sufficient research on the different regimens of therapies to determine established choices.<xref ref-type="bibr" rid="article-23569.r24">[24]</xref>&#x000a0;Cytotoxic therapies such as 5-FU or temozolomide could be possibilities in patients with advanced pNET as palliative therapy.<xref ref-type="bibr" rid="article-23569.r24">[24]</xref></p>
        <p>Some research suggests neoadjuvant therapy&#x000a0;involving peptide receptor radionuclide therapy (PRRT) in unresectable or borderline resectable pNET because of survival benefits.<xref ref-type="bibr" rid="article-23569.r38">[38]</xref><xref ref-type="bibr" rid="article-23569.r39">[39]</xref>&#x000a0;PRRT can also control hypoglycemia in malignant insulinomas,&#x000a0;but&#x000a0;its role in insulinoma treatment&#x000a0;still&#x000a0;needs more investigation.<xref ref-type="bibr" rid="article-23569.r19">[19]</xref><xref ref-type="bibr" rid="article-23569.r38">[38]</xref><xref ref-type="bibr" rid="article-23569.r40">[40]</xref></p>
      </sec>
      <sec id="article-23569.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Persistent hyperinsulinemic hypoglycemia of infancy (PHHI)</p>
          </list-item>
          <list-item>
            <p>Noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS)</p>
          </list-item>
          <list-item>
            <p>Post-gastric bypass hypoglycemia</p>
          </list-item>
          <list-item>
            <p>Factitious use of insulin</p>
          </list-item>
          <list-item>
            <p>Sulfonylurea-induced hypoglycemia</p>
          </list-item>
          <list-item>
            <p>Insulin autoimmune hypoglycemia</p>
          </list-item>
          <list-item>
            <p>Non-islet-cell tumors that secrete insulin-like growth factors (IGF)</p>
          </list-item>
          <list-item>
            <p>Nesidioblastosis<xref ref-type="bibr" rid="article-23569.r41">[41]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23569.s9" sec-type="Staging">
        <title>Staging</title>
        <p>Researchers have developed several classification and grading systems (WHO2010, ENETs, AJCC) for pNET. Most of them provide essential prognostic values.<xref ref-type="bibr" rid="article-23569.r19">[19]</xref></p>
        <p>Newer classification systems include WHO2017 and AJCC 8 edition. AJCC (8th edition, 2017) includes ENETs definitions for T stage and prognostic stage grouping. Further modification of this staging system is available, which might provide better prognostic information.<xref ref-type="bibr" rid="article-23569.r42">[42]</xref></p>
        <p>
<bold>TNM Staging</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>TX - Tumor cannot be assessed</p>
          </list-item>
          <list-item>
            <p>T1 - Tumor limited to the pancreas, less than 2 cm</p>
          </list-item>
          <list-item>
            <p>T2 -&#x000a0;Tumor limited to the pancreas, 2 to 4 cm</p>
          </list-item>
          <list-item>
            <p>T3 -&#x000a0;Tumor limited to the pancreas, greater than 4 cm; or tumor invading the duodenum or common bile duct</p>
          </list-item>
          <list-item>
            <p>T4 - Tumor invasion of adjacent organs (e.g., stomach, spleen, colon, adrenal gland) or the walls of large vessels (celiac axis or the superior mesenteric artery)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>NX - Regional lymph nodes cannot be assessed</p>
          </list-item>
          <list-item>
            <p>N0 - No regional lymph node involvement</p>
          </list-item>
          <list-item>
            <p>N1 - Regional lymph node involvement</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>M0 - No distant metastasis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>M1 - Distant metastasis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>M1a - Metastasis confined to the liver</p>
          </list-item>
          <list-item>
            <p>M1b - Metastasis in at least one extrahepatic site (e.g., lung, ovary, nonregional lymph node, peritoneum, bone)</p>
          </list-item>
          <list-item>
            <p>M1c - Both hepatic and extrahepatic metastases</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23569.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>In insulinoma patients, the 10-year survival rate is 88% after successful surgical removal, and 87.5% of patients get cured (being free of symptoms for at least six months) after surgery.<xref ref-type="bibr" rid="article-23569.r3">[3]</xref><xref ref-type="bibr" rid="article-23569.r43">[43]</xref><xref ref-type="bibr" rid="article-23569.r3">[3]</xref>&#x000a0;The 10-year survival in malignant insulinomas was 29% after successful surgical removal in one study, and the 5-year survival was 24% in another.<xref ref-type="bibr" rid="article-23569.r3">[3]</xref><xref ref-type="bibr" rid="article-23569.r5">[5]</xref> Patients with MEN1 syndrome or malignant insulinomas have a higher rate of failing initial surgery or&#x000a0;experiencing recurrent disease.<xref ref-type="bibr" rid="article-23569.r3">[3]</xref>&#x000a0;The recurrence rate among patients with MEN1 is around 21% at 10 and 20 years, while those without MEN 1 are reported at 5% at ten years and 7% at 20 years.<xref ref-type="bibr" rid="article-23569.r3">[3]</xref></p>
      </sec>
      <sec id="article-23569.s11" sec-type="Complications">
        <title>Complications</title>
        <p>The complications associated with insulinoma include persistent hypoglycemia causing interference with daily activities, irreversible neurocognitive impairment, and even death.</p>
      </sec>
      <sec id="article-23569.s12" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Insulinoma patients without MEN1 should have a&#x000a0;follow-up at 3 to 6 months post-resection.<xref ref-type="bibr" rid="article-23569.r4">[4]</xref>&#x000a0;Biochemical testing and imaging studies should be repeated at the&#x000a0;follow-up visit. If cured, patients can be followed as needed if they experience&#x000a0;recurrence of symptoms. Patients with persistent symptoms after surgery might have multiple tumors or MEN1 syndrome and should&#x000a0;receive&#x000a0;repeat imaging studies.<xref ref-type="bibr" rid="article-23569.r24">[24]</xref>&#x000a0;Patients with multiple insulinomas or MEN1 should be followed yearly, even if they&#x000a0;continue to be cured post-resection.<xref ref-type="bibr" rid="article-23569.r4">[4]</xref></p>
      </sec>
      <sec id="article-23569.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients and family members should receive education about recognizing symptoms associated with hypoglycemia and also&#x000a0;be trained to use convenient ways to correct hypoglycemia quickly. Patients should follow up with endocrinology specialists for evaluation and treatment of insulinoma. Genetic testing is sometimes necessary.</p>
      </sec>
      <sec id="article-23569.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The evaluation of insulinoma includes biochemical testing and localization with imaging studies. An interprofessional healthcare team, including primary care clinicians (MDs, DOs, NPs, and PAs), specialists (endocrinologists&#x000a0;and oncologists), radiologists, surgeons, specialty-trained nurses, pharmacists, and sometimes genetic specialists, could facilitate better management of insulinomas.&#x000a0;</p>
        <p>Patient education is paramount; therefore, every interprofessional team member must educate the patient whenever possible and is also responsible for tracking patient progress or lack thereof. Any changes in status should be recorded in the patient's health record and immediately reported to other team members so therapeutic changes can be implemented, if necessary. The length of follow-up required post-resection varies, and a timely treatment plan adjustment is more accessible if patients follow up as instructed. This kind of interprofessional teamwork and case management will improve outcomes for patients with insulinomas. [Level 5]</p>
      </sec>
      <sec id="article-23569.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23569&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23569">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/insulinoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23569">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23569/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23569">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23569.s16">
        <title>References</title>
        <ref id="article-23569.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minn</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Kayton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lorang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Harlan</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Libutti</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Shalev</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Insulinomas and expression of an insulin splice variant.</article-title>
            <source>Lancet</source>
            <year>2004</year>
            <month>Jan</month>
            <day>31</day>
            <volume>363</volume>
            <issue>9406</issue>
            <fpage>363</fpage>
            <page-range>363-7</page-range>
            <pub-id pub-id-type="pmid">15070567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gorden</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Libutti</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Insulinoma: pathophysiology, localization and management.</article-title>
            <source>Future Oncol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>229</fpage>
            <page-range>229-37</page-range>
            <pub-id pub-id-type="pmid">20146582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Service</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study.</article-title>
            <source>Mayo Clin Proc</source>
            <year>1991</year>
            <month>Jul</month>
            <volume>66</volume>
            <issue>7</issue>
            <fpage>711</fpage>
            <page-range>711-9</page-range>
            <pub-id pub-id-type="pmid">1677058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salazar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wiedenmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rindi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: an update.</article-title>
            <source>Neuroendocrinology</source>
            <year>2012</year>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>71</fpage>
            <page-range>71-3</page-range>
            <pub-id pub-id-type="pmid">22262042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Placzkowski</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Vella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Reading</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Charboneau</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Service</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>94</volume>
            <issue>4</issue>
            <fpage>1069</fpage>
            <page-range>1069-73</page-range>
            <pub-id pub-id-type="pmid">19141587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prat&#x000f2;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Didonna</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Garletti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marfia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barbaresi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garzia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ciniglio Appiani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Riboldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vigna</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Loss of consciousness in a helicopter pilot as plausible first sign of insulinoma: a case report.</article-title>
            <source>Med Lav</source>
            <year>2022</year>
            <month>Feb</month>
            <day>22</day>
            <volume>113</volume>
            <issue>1</issue>
            <fpage>e2022007</fpage>
            <pub-id pub-id-type="pmid">35226655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karanth</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Maribashetti</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic neuroendocrine tumour-insulinoma masquerading as a psychiatric illness.</article-title>
            <source>BMJ Case Rep</source>
            <year>2022</year>
            <month>Jun</month>
            <day>14</day>
            <volume>15</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">35701018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vinik</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Woltering</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Dorisio</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Wiseman</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Go</surname>
                <given-names>VL</given-names>
              </name>
              <collab>North American Neuroendocrine Tumor Society (NANETS)</collab>
            </person-group>
            <article-title>NANETS consensus guidelines for the diagnosis of neuroendocrine tumor.</article-title>
            <source>Pancreas</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>713</fpage>
            <page-range>713-34</page-range>
            <pub-id pub-id-type="pmid">20664471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cryer</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Axelrod</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Montori</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Seaquist</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Service</surname>
                <given-names>FJ</given-names>
              </name>
              <collab>Endocrine Society</collab>
            </person-group>
            <article-title>Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>94</volume>
            <issue>3</issue>
            <fpage>709</fpage>
            <page-range>709-28</page-range>
            <pub-id pub-id-type="pmid">19088155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>ASGE Standards of Practice Committee</collab>
              <name>
                <surname>Eloubeidi</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Decker</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Chandrasekhara</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chathadi</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Early</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fanelli</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Foley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Jue</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Lightdale</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Pasha</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Saltzman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Sharaf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shergill</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Cash</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>DeWitt</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia.</article-title>
            <source>Gastrointest Endosc</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-28</page-range>
            <pub-id pub-id-type="pmid">26706297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Virgolini</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Traub-Weidinger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Decristoforo</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Nuclear medicine in the detection and management of pancreatic islet-cell tumours.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>213</fpage>
            <page-range>213-27</page-range>
            <pub-id pub-id-type="pmid">15763696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christ</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wild</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Forrer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Br&#x000e4;ndle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sahli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Clerici</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gloor</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Martius</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maecke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reubi</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Glucagon-like peptide-1 receptor imaging for localization of insulinomas.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>94</volume>
            <issue>11</issue>
            <fpage>4398</fpage>
            <page-range>4398-405</page-range>
            <pub-id pub-id-type="pmid">19820010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kiesewetter</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.</article-title>
            <source>J Nucl Med</source>
            <year>2016</year>
            <month>May</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>715</fpage>
            <page-range>715-20</page-range>
            <pub-id pub-id-type="pmid">26795291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Majmundar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purandare</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ramteke-Jadhav</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lila</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bandgar</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Exendin-4-based imaging in insulinoma localization: Systematic review and meta-analysis.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>354</fpage>
            <page-range>354-364</page-range>
            <pub-id pub-id-type="pmid">33386617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Imperiale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boursier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sahakian</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ouvrard</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chevalier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sebag</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Addeo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ta&#x000ef;eb</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Value of <sup>68</sup>Ga-DOTATOC and Carbidopa-Assisted <sup>18</sup>F-DOPA PET/CT for Insulinoma Localization.</article-title>
            <source>J Nucl Med</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>384</fpage>
            <page-range>384-388</page-range>
            <pub-id pub-id-type="pmid">34272321</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murakami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fujimoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hamamatsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamauchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kodama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujita</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fujikura</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nakamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saji</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Inagaki</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Distinctive detection of insulinoma using [<sup>18</sup>F]FB(ePEG12)12-exendin-4 PET/CT.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Jul</month>
            <day>22</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>15014</fpage>
            <pub-id pub-id-type="pmid">34294854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khashab</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lennon</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Amateau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hruban</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Olino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Giday</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Wolfgang</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Edil</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Makary</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Canto</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors.</article-title>
            <source>Gastrointest Endosc</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>691</fpage>
            <page-range>691-6</page-range>
            <pub-id pub-id-type="pmid">21067742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marx</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trosic-Ivanisevic</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Caillol</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Demartines</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schoepfer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pesenti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ratone</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giovannini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Godat</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>EUS-guided radiofrequency ablation for pancreatic insulinoma: experience in 2 tertiary centers.</article-title>
            <source>Gastrointest Endosc</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>95</volume>
            <issue>6</issue>
            <fpage>1256</fpage>
            <page-range>1256-1263</page-range>
            <pub-id pub-id-type="pmid">34902374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bartsch</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Capdevila</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kos-Kudla</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rindi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kl&#x000f6;ppel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kianmanesh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
              <collab>Vienna Consensus Conference participants</collab>
            </person-group>
            <article-title>ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.</article-title>
            <source>Neuroendocrinology</source>
            <year>2016</year>
            <volume>103</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-71</page-range>
            <pub-id pub-id-type="pmid">26742109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jonkers</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Claessen</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Perren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>de Krijger</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Verhofstad</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Hermus</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kummer</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Skogseid</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Volante</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Voogd</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Ramaekers</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Speel</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>769</fpage>
            <page-range>769-79</page-range>
            <pub-id pub-id-type="pmid">17914106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>C&#x000e2;mara-de-Souza</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Toyoshima</surname>
                <given-names>MTK</given-names>
              </name>
              <name>
                <surname>Giannella</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Freire</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Camacho</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Louren&#x000e7;o</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Rocha</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Bacchella</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jureidini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>MCC</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>MQ</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>MAA</given-names>
              </name>
            </person-group>
            <article-title>Insulinoma: A retrospective study analyzing the differences between benign and malignant tumors.</article-title>
            <source>Pancreatology</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>298</fpage>
            <page-range>298-303</page-range>
            <pub-id pub-id-type="pmid">29452754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kurakawa</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Konishi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Michihata</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Matsui</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fushimi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamauchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nangaku</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yasunaga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kadowaki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Clinical Characteristics and Incidences of Benign and Malignant Insulinoma Using a National Inpatient Database in Japan.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2021</year>
            <month>Nov</month>
            <day>19</day>
            <volume>106</volume>
            <issue>12</issue>
            <fpage>3477</fpage>
            <page-range>3477-3486</page-range>
            <pub-id pub-id-type="pmid">34343300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Glasgow</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Habermann</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Lyden</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Dy</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Halfdanarson</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Vella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McKenzie</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Comparison of benign and malignant insulinoma.</article-title>
            <source>Am J Surg</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>221</volume>
            <issue>2</issue>
            <fpage>437</fpage>
            <page-range>437-447</page-range>
            <pub-id pub-id-type="pmid">32873371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kunz</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Reidy-Lagunes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Anthony</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Bertino</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Brendtro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Klimstra</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kulke</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Metz</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Sippel</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Strosberg</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>JC</given-names>
              </name>
              <collab>North American Neuroendocrine Tumor Society</collab>
            </person-group>
            <article-title>Consensus guidelines for the management and treatment of neuroendocrine tumors.</article-title>
            <source>Pancreas</source>
            <year>2013</year>
            <month>May</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>557</fpage>
            <page-range>557-77</page-range>
            <pub-id pub-id-type="pmid">23591432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>XB</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>ZD</given-names>
              </name>
            </person-group>
            <article-title>Is laparoscopic approach for pancreatic insulinomas safe? Results of a systematic review and meta-analysis.</article-title>
            <source>J Surg Res</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>186</volume>
            <issue>1</issue>
            <fpage>126</fpage>
            <page-range>126-34</page-range>
            <pub-id pub-id-type="pmid">23992857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilliaux</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hanon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Donckier</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Preoperative treatment of benign insulinoma: diazoxide or somatostatin analogues?</article-title>
            <source>Acta Chir Belg</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>122</volume>
            <issue>2</issue>
            <fpage>136</fpage>
            <page-range>136-139</page-range>
            <pub-id pub-id-type="pmid">32375590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Cong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Di</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Robotic enucleation for pediatric insulinoma with MEN1 syndrome: a case report and literature review.</article-title>
            <source>BMC Surg</source>
            <year>2018</year>
            <month>Jun</month>
            <day>19</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <pub-id pub-id-type="pmid">29921249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belfiori</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wiese</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Partelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>W&#x000e4;chter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Crippa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Falconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bartsch</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Short-Term and Long-Term Outcomes.</article-title>
            <source>World J Surg</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>10</issue>
            <fpage>3223</fpage>
            <page-range>3223-3230</page-range>
            <pub-id pub-id-type="pmid">29691623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D&#x00105;bkowski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gajewska</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Londzin-Olesik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bia&#x00142;ek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andrysiak-Mammos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kos-Kud&#x00142;a</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Starzy&#x00144;ska</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Successful EUS-guided ethanol ablation of insulinoma, four-year follow-up. Case report and literature review.</article-title>
            <source>Endokrynol Pol</source>
            <year>2017</year>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>472</fpage>
            <page-range>472-479</page-range>
            <pub-id pub-id-type="pmid">28819950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alyusuf</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Ekhzaimy</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Radiofrequency Ablation as a Primary Therapy for Benign Functioning Insulinoma.</article-title>
            <source>AACE Clin Case Rep</source>
            <year>2021</year>
            <season>Mar-Apr</season>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-157</page-range>
            <pub-id pub-id-type="pmid">34095476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jayawickreme</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Muthukuda</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Kariyawasam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Piyarisi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abeywickrama</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>A rare case of insulinoma presenting with deep vein thrombosis, successfully treated with minimally invasive procedures including microwave ablation.</article-title>
            <source>Endocrinol Diabetes Metab Case Rep</source>
            <year>2022</year>
            <month>May</month>
            <day>01</day>
            <volume>2022</volume>
            <pub-id pub-id-type="pmid">35510504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gill</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Rauf</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>MacFarlane</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <article-title>Diazoxide treatment for insulinoma: a national UK survey.</article-title>
            <source>Postgrad Med J</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>73</volume>
            <issue>864</issue>
            <fpage>640</fpage>
            <page-range>640-1</page-range>
            <pub-id pub-id-type="pmid">9497974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sivajohanathan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Asmis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hammad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zbuk</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline.</article-title>
            <source>Curr Oncol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>249</fpage>
            <page-range>249-255</page-range>
            <pub-id pub-id-type="pmid">28874893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mujica-Mota</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Varley-Campbell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tikhonova</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haasova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lucherini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Talens-Bou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sherriff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Napier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ramage</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoyle</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.</article-title>
            <source>Health Technol Assess</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>49</issue>
            <fpage>1</fpage>
            <page-range>1-326</page-range>
            <pub-id pub-id-type="pmid">30209002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lombard-Bohas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hobday</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wolin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Panneerselvam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stergiopoulos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Capdevila</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pommier</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.</article-title>
            <source>Pancreas</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-9</page-range>
            <pub-id pub-id-type="pmid">25479584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yao</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bohas</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Wolin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hobday</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Okusaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Capdevila</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Tomassetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pavel</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Hoosen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lincy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>&#x000d6;berg</surname>
                <given-names>K</given-names>
              </name>
              <collab>RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group</collab>
            </person-group>
            <article-title>Everolimus for advanced pancreatic neuroendocrine tumors.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Feb</month>
            <day>10</day>
            <volume>364</volume>
            <issue>6</issue>
            <fpage>514</fpage>
            <page-range>514-23</page-range>
            <pub-id pub-id-type="pmid">21306238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raymond</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dahan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Raoul</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Borbath</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lombard-Bohas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Metrakos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vinik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>H&#x000f6;rsch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hammel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wiedenmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patyna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Blanckmeister</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Feb</month>
            <day>10</day>
            <volume>364</volume>
            <issue>6</issue>
            <fpage>501</fpage>
            <page-range>501-13</page-range>
            <pub-id pub-id-type="pmid">21306237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hicks</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bodei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grozinsky-Glasberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Borbath</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Cwikla</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Toumpanakis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>H&#x000f6;rsch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tiensuu Janson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ramage</surname>
                <given-names>J</given-names>
              </name>
              <collab>Antibes Consensus Conference participants</collab>
            </person-group>
            <article-title>ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.</article-title>
            <source>Neuroendocrinology</source>
            <year>2017</year>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>295</fpage>
            <page-range>295-309</page-range>
            <pub-id pub-id-type="pmid">28402980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ezziddin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khalaf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vanezi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haslerud</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Al Zreiqat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Willinek</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Biersack</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Sabet</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2014</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>925</fpage>
            <page-range>925-33</page-range>
            <pub-id pub-id-type="pmid">24504504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sansovini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Severi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ambrosetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nanni</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sarnelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bodei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Garaboldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bartolomei</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paganelli</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.</article-title>
            <source>Neuroendocrinology</source>
            <year>2013</year>
            <volume>97</volume>
            <issue>4</issue>
            <fpage>347</fpage>
            <page-range>347-54</page-range>
            <pub-id pub-id-type="pmid">23392072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Obara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakayama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tsutsumi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okamura</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Adult-Onset Focal Nesidioblastosis With Nodular Formation Mimicking Insulinoma.</article-title>
            <source>J Endocr Soc</source>
            <year>2022</year>
            <month>Jan</month>
            <day>01</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>bvab185</fpage>
            <pub-id pub-id-type="pmid">35024540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Javed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Strosberg</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wolfgang</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Cives</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems.</article-title>
            <source>J Clin Oncol</source>
            <year>2017</year>
            <month>Jan</month>
            <day>20</day>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>274</fpage>
            <page-range>274-280</page-range>
            <pub-id pub-id-type="pmid">27646952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23569.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peltola</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hannula</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Huhtala</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Metso</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sand</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laukkarinen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tiikkainen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sir&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soinio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nuutila</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moilanen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Laaksonen</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Ebeling</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schalin-J&#x000e4;ntti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jaatinen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Long-term morbidity and mortality in patients diagnosed with an insulinoma.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>185</volume>
            <issue>4</issue>
            <fpage>577</fpage>
            <page-range>577-586</page-range>
            <pub-id pub-id-type="pmid">34374651</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
